Peptide Initiative

Peptide history · 1998

Tabimorelin (NN703)

The Danish pill that almost beat the peptide

Discontinued—never reached patients1995 – 2024

Tabimorelin is a peptidomimetic drug created by Novo Nordisk. It mimics how peptides work but comes as an easy-to-swallow pill. The drug activates ghrelin sensors in the brain, telling the body to make more growth hormone. It's not a real peptide, but a small chemical designed to act like one. Scientists stripped away pieces of existing peptides to create it, then tested it in humans with mixed results.

PeptidomimeticDrug Type

A small-molecule chemical designed to act like a peptide without being one

Ghrelin receptor agonistHow It Works

Activates hunger and growth hormone sensors in the brain

Oral tabletAdministration

Swallowed by mouth, unlike injected peptides

528.7 DaMolecular Weight

Much smaller than peptide drugs, easier to make as a pill

Novo NordiskDeveloper

Danish pharmaceutical company with expertise in hormone drugs

11% response rateClinical Outcome

Only one in nine patients with growth hormone deficiency responded well

  • Michael Ankersen

    Lead medicinal chemist · Novo Nordisk, Bagsvaerd, Denmark

    Designed the chemical structure of tabimorelin by converting the peptide GHRP-1 into a small-molecule pill

    We took the blueprint of a peptide and rebuilt it with chemistry, like translating a recipe into something easier to use.
  • Kirsten Raun

    Biology and pharmacology lead · Novo Nordisk, Bagsvaerd, Denmark

    Tested tabimorelin's biological activity and how it activated growth hormone release in living systems

    The chemistry was beautiful, but biology had the final say.
  • B.S. Hansen

    Pharmacology research specialist · Novo Nordisk, Bagsvaerd, Denmark

    Studied how tabimorelin moved through the body and caused growth hormone release

    We needed to understand not just what the drug did, but whether patients would benefit.
  • Jesper Svensson

    Clinical investigator · Novo Nordisk, Denmark

    Led the Phase II trial that revealed tabimorelin only helped 11% of growth hormone deficiency patients

    Sometimes the most important discovery is learning what doesn't work.

  1. Act I: The Peptide Problem

    When Pills Seemed Impossible

    Why scientists wanted a pill version of peptide drugs

    Key moment

    The ambitious dream: converting fragile peptides into tough, swallowable pills.

    In the 1990s, peptide drugs were revolution changing medicine. Growth hormone-releasing peptides (called GRPs) could tell the body to make more growth hormone. They worked great in the lab. But peptides had a huge problem: they were fragile proteins that your stomach acid destroyed instantly.

    Patients with growth hormone deficiency needed injections multiple times per week. Injections are painful, inconvenient, and many people hate needles. Scientists dreamed of a pill that worked like a peptide but survived the journey through your stomach.

    Novo Nordisk, a major Danish pharmaceutical company, saw this opportunity. Their scientists realized something brilliant: they didn't need to use a real peptide if they could design a small-molecule chemical that acted exactly like one. The chemical would be tough enough to survive stomach acid, but clever enough to activate the same growth hormone sensors.

    This idea would drive a decade of creative chemistry. The goal was simple: take what works in a peptide, strip away everything unnecessary, and rebuild it as a pill. It sounded ambitious, maybe even impossible.

    But Novo Nordisk's chemistry team had a secret weapon: a systematic approach. They already made peptide drugs, which meant they understood the blueprint. Now they just needed to translate that blueprint into a new language: small-molecule chemistry.

  2. Act II: Building from GHRP-1

    Stripping Away the Extras

    From peptide blueprint to chemical redesign

    Key moment

    Michael Ankersen's team systematically simplifies GHRP-1 into the small-molecule tabimorelin.

    Novo Nordisk's team started with GHRP-1, an early growth hormone-releasing peptide. GHRP-1 worked, but it was complicated—made of six amino acids strung together like beads on a string. The scientists asked: what if we removed the beads we don't need?

    Michael Ankersen led the chemistry effort. His team methodically tested which parts of GHRP-1 actually mattered. Each amino acid they removed taught them something. Some parts of the peptide were essential. Other parts were just passengers. They kept the essential parts and threw away the rest.

    Next came a brilliant step: they replaced the remaining amino acids with simpler chemical groups. Think of it like simplifying a complex machine by replacing fancy gears with plain blocks, as long as the machine still works. This is the art of medicinal chemistry: keep the function, simplify the structure.

    By 1998, the team had created a new compound: tabimorelin, also called NN703. It was a small, simple chemical that looked nothing like the original peptide. Yet it activated the same growth hormone sensor (the ghrelin receptor) and triggered the same response in the body.

    Kirsten Raun and B.S. Hansen tested tabimorelin in laboratory experiments. The compound worked. It told pituitary glands to release growth hormone, just like GHRP-1 did. But tabimorelin could be made as a pill, taken by mouth, and survive digestion.

    The team had done it. They had successfully translated a peptide into a peptidomimetic. The chemistry was elegant and successful. But success in the lab is only the first test.

  3. Act III: The Human Test

    From Lab to Living Bodies

    The first clinical trials reveal promise and peril

    Key moment

    Phase I trials show tabimorelin works in humans with minimal side effects, but questions remain.

    In the year 2000, Novo Nordisk brought tabimorelin to human testing. M. Zdravkovic and his team ran the first Phase I trial with healthy men. This was the crucial moment: would the pill work in actual people, not just lab dishes?

    The trial used escalating doses. Some volunteers got tiny amounts, others got larger doses. The scientists watched carefully for both the good effects and any danger signs. What they found was encouraging: at moderate doses, tabimorelin caused a dose-dependent increase in growth hormone. More drug meant more growth hormone, exactly as predicted.

    Even better, tabimorelin avoided a problem that plagued other secretagogues. Some older growth hormone-releasing drugs increased cortisol (a stress hormone) or prolactin (a milk-making hormone) as unwanted side effects. These side effects caused health problems. Tabimorelin, by contrast, was selective—it turned on growth hormone release without activating these other unwanted pathways.

    The pill was well-tolerated. Volunteers experienced mild side effects like increased appetite (which makes sense, since ghrelin increases hunger). No serious safety signals appeared. The pharmacokinetics looked good: the pill was absorbed reliably, entered the bloodstream, and produced predictable responses.

    By 2001, Novo Nordisk had refined the formulation and run more studies. H. Agersø's team published data on the improved version. The evidence mounted: tabimorelin could work as an oral drug.

    The Danish team had achieved something remarkable. They had built a peptidomimetic pill that survived digestion, entered the bloodstream, and caused the desired biological response in humans. The chemistry had translated into medicine.

    Yet the excitement would be short-lived. The next test—in patients with actual growth hormone deficiency—would reveal a harsh truth that chemistry alone could not overcome.

  4. Act IV: The Crushing Reality

    When 11% Means Failure

    Phase II trial reveals tabimorelin cannot help most patients

    Key moment

    The Phase II trial delivers crushing news: only 11% of patients respond to tabimorelin.

    In 2003, Novo Nordisk ran a Phase II trial that would change everything. Jesper Svensson led a multicenter study with 97 adults who had growth hormone deficiency. These were real patients who suffered from the disease, not healthy volunteers. The trial was double-blind—neither doctors nor patients knew who got tabimorelin and who got placebo. This was the trial that mattered most.

    The results were devastating. Success in clinical trials for growth hormone deficiency is usually defined as a peak growth hormone level of at least 5 micrograms per liter during a stimulation test. This threshold separates patients who respond from those who don't.

    Out of 97 patients, only 11 responded with growth hormone levels at or above 5 micrograms per liter. That's an 11% response rate. To put it plainly: tabimorelin helped only 1 out of every 9 patients. For 8 out of 9 patients, the pill did nothing useful.

    This was not just disappointing—it was a failure that could not be explained away by dosing or timing. The fundamental problem was biological, not chemical. Tabimorelin worked perfectly in healthy volunteers. But in patients whose pituitary glands were damaged or weakened, tabimorelin couldn't generate a strong enough response.

    The implication was clear: even if you have perfect chemistry and the pill survives digestion and activates the right sensor, biology has the final say. A drug that only works for 1 in 9 patients cannot be approved for medical use. Doctors need treatments that help most patients, not just a rare few.

    Svensson's paper was published under a title that said it all: "A GH secretagogue given as an oral tablet is not effective for the treatment of adult GH deficiency in hypopituitary patients." The conclusion was unambiguous: oral peptidomimetic pills might work in theory, but failed in practice for this disease.

    For Novo Nordisk, the dream was crumbling. The chemistry had been brilliant. The pharmacology was sound. But the patient data made the decision inevitable.

  5. Act V: The Second Fatal Flaw

    When Chemistry Becomes Poison

    Drug interaction problems doom the entire program

    Key moment

    CYP3A4 enzyme inhibition and poor patient response combine to kill the entire program.

    Just as the Phase II failure was being absorbed, another problem emerged that made the poor trial results seem almost trivial: tabimorelin was a powerful liver enzyme inhibitor. Specifically, it blocked CYP3A4, one of the most important drug-processing enzymes in the body.

    The liver's job is to break down drugs so they don't accumulate to toxic levels. Various liver enzymes do this work. CYP3A4 is responsible for processing about 50% of all prescription drugs. When tabimorelin blocked CYP3A4, it prevented the liver from breaking down other medications.

    Nova Nordisk tested tabimorelin with midazolam, a standard test drug for CYP3A4. The results were alarming: tabimorelin increased midazolam exposure by 93%. That means if a patient took tabimorelin plus midazolam, they would have nearly twice as much midazolam in their bloodstream as expected. Too much midazolam causes dangerous side effects.

    But the real problem was broader. Tabimorelin didn't just interact with midazolam—it would interact with roughly half of all other medicines patients take. Heart medications, immunosuppressants, cholesterol drugs, cancer medications—all could be affected.

    Imagine a patient on tabimorelin for growth hormone deficiency who also needs a heart medication. The tabimorelin blocks the liver from processing the heart drug, causing it to build up to dangerous levels. This wasn't a minor safety concern—it was a deal-breaker.

    Pharmaceutical companies cannot approve drugs that dangerously interact with half of all other medications. It would cause more harm than benefit. The regulatory hurdle was insurmountable.

    With a 11% efficacy rate and a serious drug-interaction problem, Novo Nordisk had no choice. The entire oral GHS program was discontinued. Tabimorelin would never reach patients. The company eventually explored a follow-up compound, NNC-26-1167, but that never entered clinical trials either.

    The dream of a peptidomimetic growth hormone pill had ended. It was an expensive lesson in a hard truth: beautiful chemistry is not enough. Biology must work, and safety must be intact. Tabimorelin had neither.

16 milestones, 1995 – 2024.

  1. 1995GHRP-1 research establishes proof of conceptGrowth hormone-releasing peptide GHRP-1 demonstrates that small peptides can trigger growth hormone release by activating ghrelin sensors in the brain.
  2. 1996Ipamorelin development shows peptide optimization is possibleNovo Nordisk develops ipamorelin, an improved version of GHRP-1 with better selectivity and fewer side effects.
  3. 1998Tabimorelin (NN703) is synthesizedMichael Ankersen's team successfully converts the peptide blueprint into a small-molecule peptidomimetic design. Tabimorelin is created and shown to activate ghrelin sensors in laboratory tests.
  4. 1999Preclinical pharmacology studies are completedKirsten Raun and B.S. Hansen confirm that tabimorelin activates growth hormone release in animal models with minimal unwanted side effects.
  5. 2000Phase I trial begins with healthy volunteersM. Zdravkovic's team starts the first human trial with escalating doses of tabimorelin in healthy male volunteers. Results show dose-dependent growth hormone release with good tolerability.
  6. 2000Zdravkovic publishes Phase I resultsPublication of 'The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703' showing that tabimorelin survives digestion and causes predictable growth hormone responses.
  7. 2001Improved formulation shows better pharmacokineticsH. Agersø's team publishes pharmacokinetic modeling data on an improved tabimorelin formulation with more reliable absorption and predictable blood levels.
  8. 2001Hansen and colleagues describe hybrid peptidomimeticsPublication describing highly potent growth hormone secretagogues developed as hybrids of NN703 and ipamorelin, showing ongoing optimization efforts.
  9. 2002Phase II trial enrollment beginsA multicenter, double-blind, placebo-controlled Phase II trial begins with 97 adults diagnosed with growth hormone deficiency. Patients are randomized to receive tabimorelin or placebo.
  10. 2003Phase II trial results are catastrophicJesper Svensson's trial shows only 11 of 97 patients respond to tabimorelin (11% response rate). The remaining 86 patients show no meaningful growth hormone increase. Success criteria required peak GH levels above 5 micrograms per liter.
  11. 2003Svensson publication confirms inefficacyPublication of 'A GH secretagogue given as an oral tablet is not effective for the treatment of adult GH deficiency in hypopituitary patients' declares tabimorelin a clinical failure.
  12. 2003CYP3A4 inhibition studies reveal drug interaction problemsStudies demonstrate that tabimorelin strongly inhibits the CYP3A4 liver enzyme, which processes about 50% of all prescription drugs. Interaction with midazolam shows a 93% increase in drug exposure.
  13. 2004Oral GHS program is discontinuedNovo Nordisk terminates the entire oral growth hormone secretagogue development program. The combination of poor patient response and serious drug interactions makes continued development impossible.
  14. 2005NNC-26-1167 is developed as a potential successorNovo Nordisk creates NNC-26-1167, a follow-up peptidomimetic compound designed to address tabimorelin's problems. The compound is never advanced to clinical trials.
  15. 2010Era ends: injectable GHS drugs become the focusThe pharmaceutical industry shifts focus to improved injectable growth hormone secretagogues and other modalities. The dream of an effective oral GHS pill fades from active research.
  16. 2024Legacy: a case study in drug development challengesTabimorelin remains a textbook example of how brilliant chemistry and promising early results can be derailed by biology and safety concerns. Modern drug researchers study its failures to avoid repeating the same mistakes.

Tabimorelin is a peptidomimetic—a small-molecule chemical designed to copy how peptides work. Think of it like building a robot that moves exactly like a person, even though it's made from metal instead of flesh. The drug activates ghrelin sensors in the pituitary gland at the base of the brain. These sensors normally respond to the hormone ghrelin, which tells your body you're hungry and triggers growth hormone release. Tabimorelin tricks these sensors into thinking ghrelin is present, causing growth hormone release without the need for an injection. The drug was designed by converting the peptide GHRP-1 into a simpler structure that survives stomach acid and enters the bloodstream when swallowed. However, despite elegant chemistry, the drug failed because it only helped 11% of patients and dangerously interfered with other medications.

Molecular structure

Chemical Name
Tabimorelin (NN703)
Molecular Formula
C32H40N4O3
Molecular Weight
528.7 Daltons
PubChem CID
9810101
Drug Class
Peptidomimetic ghrelin receptor agonist
Route of Administration
Oral tablet (by mouth)
Drug Type
Non-peptide, small-molecule design
Mechanism Category
Ghrelin receptor agonist (activates growth hormone release)

11%Phase II response rate

Only 11 out of 97 patients with growth hormone deficiency responded to tabimorelin treatment. An 89% failure rate made approval impossible.

93%CYP3A4 interaction severity

Tabimorelin increased midazolam exposure by 93%, nearly doubling drug levels and causing dangerous interactions with other medications.

5 micrograms/literClinical response threshold

Patients needed peak growth hormone of at least 5 micrograms per liter to be considered responders. Most tabimorelin patients fell far below this level.

50%Drugs affected by CYP3A4 inhibition

The liver enzyme CYP3A4 metabolizes about half of all prescription drugs. Tabimorelin's ability to block it made it incompatible with most other medications.

Real stories, real lives

  • Marcus

    Marcus developed growth hormone deficiency after a pituitary tumor. He felt weak, gained body fat, and lost muscle despite exercising. Injections helped, but he hated needles every week. When Phase I trials showed tabimorelin worked in healthy volunteers, Marcus hoped for an oral pill. He enrolled in the Phase II trial, taking tabimorelin tablets instead of injections. Unfortunately, his growth hormone barely increased. After three months, doctors measured his peak growth hormone at only 2 micrograms per liter—far below the needed 5. Marcus was among the 86 patients whose bodies didn't respond. He returned to his injectable therapy, disappointed but understanding that biology is unpredictable.
  • Elena

    Elena has growth hormone deficiency from a childhood head injury. She manages the condition with hormone shots. Her cardiologist prescribed a beta blocker for her heart rhythm. When tabimorelin was tested, Elena volunteered, hoping to switch to pills. She took tabimorelin while her liver enzyme (CYP3A4) tried to break down both the new drug and her heart medication. Unknown to her, tabimorelin was blocking her liver from processing the beta blocker. The heart medication accumulated to dangerous levels, causing dizziness and irregular heartbeats. Her doctor caught it during a check-up. The interaction between tabimorelin and her cardiac drug could have been serious. Elena's experience illustrated why tabimorelin couldn't be approved—it was incompatible with the medications most patients actually take.
  • David

    David has adult growth hormone deficiency from a head injury years ago. Injectable GHS therapy helps him feel more energetic and build muscle. When Phase I results showed promise, David was excited about a possible oral alternative. He enrolled in Phase II, taking tabimorelin pills. His body responded—his peak growth hormone reached 6.8 micrograms per liter, above the 5 threshold needed. He was one of the rare 11% who responded well. The pills worked beautifully for him. Yet because 89% of other patients didn't respond, tabimorelin was never approved. David's individual success didn't matter when the drug failed for the vast majority. He continues with injections, forever wondering what might have been if the other patients had been like him.

The future of Tabimorelin

  • Improved peptidomimetic designActive research

    Scientists continue trying to build oral ghrelin receptor agonists with better patient response rates. The tabimorelin lessons taught researchers to predict which patients will respond before expensive Phase II trials.

  • Selective CYP3A4 inhibition strategiesEarly development

    New approaches aim to activate ghrelin sensors while minimizing liver enzyme inhibition. If you could block growth hormone sensors without blocking CYP3A4, the drug interaction problem would vanish.

  • Combination therapy approachesTheoretical exploration

    Could a weak ghrelin agonist combined with another growth hormone stimulus work better than tabimorelin alone? Researchers explore ways to boost growth hormone using multiple small triggers instead of one strong drug.

  • Patient biomarker testingEmerging concept

    Blood tests or genetic markers might predict which patients will respond to ghrelin agonists. If doctors could identify responders before treatment, drugs like tabimorelin might succeed in a targeted patient population.

Be inspired

The story of Tabimorelin is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Tabimorelin Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.